Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

REGAIN Study Group

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)976-986
Number of pages11
JournalThe Lancet Neurology
Volume16
Issue number12
DOIs
StatePublished - Dec 1 2017

ASJC Scopus Subject Areas

  • Clinical Neurology

Cite this